<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Avita Medical Ltd — News on 6ix</title>
<link>https://6ix.com/company/avita-medical-ltd</link>
<description>Latest news and press releases for Avita Medical Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/avita-medical-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b5ec78dffbe2df113daf.webp</url>
<title>Avita Medical Ltd</title>
<link>https://6ix.com/company/avita-medical-ltd</link>
</image>
<item>
<title>AVITA Medical to Announce First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-to-announce-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-to-announce-first-quarter-2026-financial-results</guid>
<pubDate>Thu, 23 Apr 2026 20:10:00 GMT</pubDate>
<description>VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent</description>
</item>
<item>
<title>AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-positive-interim-results-from-cohealyxr-study-demonstrating-accelerated-time-to-skin-grafting</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-positive-interim-results-from-cohealyxr-study-demonstrating-accelerated-time-to-skin-grafting</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Mean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction)Median time to graft of 11 days, with grafting as early as 5</description>
</item>
<item>
<title>AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-secures-10-year-barda-agreement-worth-up-to-dollar255m-to-bolster-us-burn-emergency-preparedness</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-secures-10-year-barda-agreement-worth-up-to-dollar255m-to-bolster-us-burn-emergency-preparedness</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year</description>
</item>
<item>
<title>AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Cohealyx® multi-center study interim analysis and new case data to be presentedRECELL® and PermeaDerm® data reinforce a comprehensive approach to wound</description>
</item>
<item>
<title>AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-to-participate-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-to-participate-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:15:00 GMT</pubDate>
<description>VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O’Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. AVITA Medical management is scheduled to participate in a presentation and fireside chat on Wednesday, March 4, at 8:10 a.m. Pacific Time / 11:10 a.m. East</description>
</item>
<item>
<title>AVITA Medical to Host Investor Webinar Briefing</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-host-investor-webinar-141500536</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-host-investor-webinar-141500536</guid>
<pubDate>Fri, 13 Feb 2026 14:15:00 GMT</pubDate>
<description>VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time</description>
</item>
<item>
<title>AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-reports-fourth-quarter-210100624</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-reports-fourth-quarter-210100624</guid>
<pubDate>Thu, 12 Feb 2026 21:01:00 GMT</pubDate>
<description>VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights and Recent Business Updates Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering imp</description>
</item>
<item>
<title>Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies</title>
<link>https://6ix.com/company/avita-medical-ltd/news/data-2026-boswick-burn-wound-223000056</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/data-2026-boswick-burn-wound-223000056</guid>
<pubDate>Sun, 25 Jan 2026 22:30:00 GMT</pubDate>
<description>First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound</description>
</item>
<item>
<title>AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-pre-j-p-132500321</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-pre-j-p-132500321</guid>
<pubDate>Tue, 13 Jan 2026 13:25:00 GMT</pubDate>
<description>VALENCIA, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal year 2025. The Company also provided its preliminary outlook for fiscal year 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. Pacific Ti</description>
</item>
<item>
<title>AVITA Medical Announces Changes to its Board of Directors</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-changes-board-210500807</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-changes-board-210500807</guid>
<pubDate>Mon, 05 Jan 2026 21:05:00 GMT</pubDate>
<description>Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. “We are pleased to welcome Joe to the Board.</description>
</item>
<item>
<title>AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-present-44th-annual-211500324</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-present-44th-annual-211500324</guid>
<pubDate>Thu, 18 Dec 2025 21:15:00 GMT</pubDate>
<description>VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time. A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at htt</description>
</item>
<item>
<title>AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-present-piper-sandler-211500462</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-present-piper-sandler-211500462</guid>
<pubDate>Mon, 24 Nov 2025 21:15:00 GMT</pubDate>
<description>VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m. EST. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live audio webcast of the presentation w</description>
</item>
<item>
<title>AVITA® Medical Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-reports-third-quarter-210500379</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-reports-third-quarter-210500379</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>VALENCIA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2025. Financial Results Commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024.Cash, cash equivalents, and marketable securities totaled $23.3 million as of Sept</description>
</item>
<item>
<title>Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment</title>
<link>https://6ix.com/company/avita-medical-ltd/news/data-presented-2025-southern-region-133000454</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/data-presented-2025-southern-region-133000454</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populationsVALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the clinical and economic v</description>
</item>
<item>
<title>AVITA Medical to Announce Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-announce-third-quarter-201500194</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-announce-third-quarter-201500194</guid>
<pubDate>Wed, 29 Oct 2025 20:15:00 GMT</pubDate>
<description>VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 7, 2025, at 8:30 a.m.</description>
</item>
<item>
<title>AVITA Medical Welcomes Support for RECELL® in Burns in Australia</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-welcomes-support-recell-203000978</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-welcomes-support-recell-203000978</guid>
<pubDate>Tue, 28 Oct 2025 20:30:00 GMT</pubDate>
<description>Australia’s Medical Services Advisory Committee (MSAC) recognizes RECELL® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia’s Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) t</description>
</item>
<item>
<title>AVITA Medical Announces CEO Transition</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-ceo-transition-221500740</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-announces-ceo-transition-221500740</guid>
<pubDate>Thu, 16 Oct 2025 22:15:00 GMT</pubDate>
<description>Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effec</description>
</item>
<item>
<title>CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds</title>
<link>https://6ix.com/company/avita-medical-ltd/news/cms-technology-add-payment-expands-123000798</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/cms-technology-add-payment-expands-123000798</guid>
<pubDate>Wed, 01 Oct 2025 12:30:00 GMT</pubDate>
<description>Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers, supporting broader use of RECELL VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today announced that beginning October 1, 2025, hospitals across the U.S. will be eligible for New</description>
</item>
<item>
<title>AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe</title>
<link>https://6ix.com/company/avita-medical-ltd/news/avita-medical-receives-ce-mark-230000232</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/avita-medical-receives-ce-mark-230000232</guid>
<pubDate>Sun, 14 Sep 2025 23:00:00 GMT</pubDate>
<description>VALENCIA, Calif., Sept. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialize RECELL GO in Europe and in other markets that recognize the CE Mark. “CE Mark for RECELL® GO is an important milestone for AVITA Medical and for patients,” s</description>
</item>
<item>
<title>Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System</title>
<link>https://6ix.com/company/avita-medical-ltd/news/real-world-data-shows-significant-114500806</link>
<guid isPermaLink="true">https://6ix.com/company/avita-medical-ltd/news/real-world-data-shows-significant-114500806</guid>
<pubDate>Thu, 04 Sep 2025 11:45:00 GMT</pubDate>
<description>Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin graftingMore than $42,000 per patient cost savings, together with improved patient throughput, support operational and economic value Presented at the 2025 European Burn Association Congress in Berlin, Germany VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic</description>
</item>
</channel>
</rss>